Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et al.
Takeda Global Research & Development Centre (Europe) Ltd., 61 Aldwych, London, UK. a.beiderbeck@tgrd.com
Annette B
AB
Beiderbeck
Motonobu
M
Sakaguchi
D016907:Adverse Drug Reaction Reporting Systems; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017093:Liver Failure / Q000139:chemically induced*; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone